ATE312176T1 - Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien - Google Patents

Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien

Info

Publication number
ATE312176T1
ATE312176T1 AT01927769T AT01927769T ATE312176T1 AT E312176 T1 ATE312176 T1 AT E312176T1 AT 01927769 T AT01927769 T AT 01927769T AT 01927769 T AT01927769 T AT 01927769T AT E312176 T1 ATE312176 T1 AT E312176T1
Authority
AT
Austria
Prior art keywords
factor viii
human cell
production
blood clotting
muteins
Prior art date
Application number
AT01927769T
Other languages
English (en)
Inventor
Charlotte Hauser
Andrea Hoerster
Carola Schroeder
Michael Lehnerer
Original Assignee
Octagene Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00106225A external-priority patent/EP1136553A1/de
Application filed by Octagene Gmbh filed Critical Octagene Gmbh
Application granted granted Critical
Publication of ATE312176T1 publication Critical patent/ATE312176T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AT01927769T 2000-03-22 2001-03-21 Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien ATE312176T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00106225A EP1136553A1 (de) 2000-03-22 2000-03-22 Herstellung von rekombinanten Blutgerinnungsfaktoren in humanen Zellinien
US20324900P 2000-05-08 2000-05-08
PCT/EP2001/003220 WO2001070968A2 (en) 2000-03-22 2001-03-21 Production of recombinant blood clotting factors in human cell lines

Publications (1)

Publication Number Publication Date
ATE312176T1 true ATE312176T1 (de) 2005-12-15

Family

ID=26070708

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01927769T ATE312176T1 (de) 2000-03-22 2001-03-21 Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien

Country Status (28)

Country Link
US (1) US7572619B2 (de)
EP (2) EP1266006B1 (de)
JP (1) JP3894795B2 (de)
KR (1) KR100581574B1 (de)
CN (1) CN1454257B (de)
AT (1) ATE312176T1 (de)
AU (3) AU5471501A (de)
BE (1) BE2014C077I2 (de)
BG (1) BG65930B1 (de)
BR (1) BRPI0109494B8 (de)
CA (1) CA2404163C (de)
CZ (1) CZ303929B6 (de)
DE (1) DE60115613T2 (de)
DK (1) DK1266006T3 (de)
EA (1) EA004317B1 (de)
EE (1) EE200200538A (de)
ES (1) ES2254403T3 (de)
FR (1) FR15C0003I2 (de)
HR (1) HRP20020767B1 (de)
HU (1) HU228091B1 (de)
IL (2) IL151857A0 (de)
MX (1) MXPA02009221A (de)
NO (1) NO330910B1 (de)
NZ (1) NZ521732A (de)
RS (1) RS50743B (de)
SI (1) SI1266006T1 (de)
SK (1) SK287706B6 (de)
WO (1) WO2001070968A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572619B2 (en) * 2000-03-22 2009-08-11 Octagene Gmbh Recombinant blood clotting factors
EP1319016A4 (de) * 2000-09-19 2006-05-10 Univ Emory Modifizierter faktor viii
EP1469064A1 (de) 2003-04-15 2004-10-20 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Expression von Proteinen in endothelialen Zellen, die von Vorläuferzellen aus Nabelschnurblut abgeleitet wurden
US7425539B2 (en) 2004-03-19 2008-09-16 Baxter International Inc. Factor IXa for the treatment of bleeding disorders
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
DK1804839T3 (da) 2004-09-22 2012-04-10 St Jude Childrens Res Hospital Forbedret ekspression af faktor ix i genterapivektorer
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
ES2380485T3 (es) * 2005-02-11 2012-05-14 Novo Nordisk Health Care Ag Producción de un polipéptido en un líquido de cultivo sin suero con hidrolizado de proteínas vegetales
EP1707634A1 (de) 2005-03-29 2006-10-04 Octapharma AG Verfahren zur Isolierung von rekombinant hergestellten Proteinen
EP1739179A1 (de) 2005-06-30 2007-01-03 Octapharma AG Serumfreie stabile Transfektion und Produktion von rekombinanten humanen Proteinen in humanen Zelllinien
KR101495549B1 (ko) 2006-07-13 2015-02-25 와이어쓰 엘엘씨 당단백질의 생산
CA2683423C (en) * 2007-04-26 2020-10-27 Inspiration Biopharmaceuticals, Inc. Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
US20110045535A1 (en) * 2007-08-27 2011-02-24 National University Corporation Nagoya University Activator for Blood Coagulation Factor VII Promoter and Utilization of the Same
JP2012500250A (ja) 2008-08-21 2012-01-05 オクタファルマ アクチェン ゲゼルシャフト 組換えにより産生したヒト第ｖｉｉｉ及び第ｉｘ因子
WO2010092135A2 (en) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
DK2482841T4 (da) 2009-10-02 2022-10-24 Childrens Hospital Philadelphia Sammensætninger og fremgangsmåder til at forbedre koagulationsfaktor-viii-funktion
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
BRPI1105317A2 (pt) * 2011-01-24 2013-04-30 Fundacco Hemoct De Ribeirco Preto produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1
CA2827923C (en) 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
CN102199607B (zh) * 2011-03-30 2012-11-14 山西大学 重组人凝血因子ix小基因及其ptc突变体稳定细胞株
CA2835053C (en) 2011-05-13 2020-07-07 Octapharma Ag A method of increasing the productivity of eucaryotic cells in the production of recombinant fviii
TW201307563A (zh) * 2011-05-19 2013-02-16 Shire Human Genetic Therapies 純化乙醯肝素－ｎ－硫酸酯酶之方法
JP5997151B2 (ja) 2011-06-30 2016-09-28 中外製薬株式会社 ヘテロ二量化ポリペプチド
CN102321668A (zh) * 2011-07-06 2012-01-18 中国人民解放军军事医学科学院野战输血研究所 一种表达重组人凝血因子ⅶ的方法及其专用载体
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
CA2850579A1 (en) 2011-10-18 2013-04-25 Carsten Horn Method for improving the stability of purified factor viii after reconstitution
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
CA3233142A1 (en) 2011-11-30 2013-06-06 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
WO2013125667A1 (ja) 2012-02-24 2013-08-29 中外製薬株式会社 FcγRIIBを介して抗原の消失を促進する抗原結合分子
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
US9550819B2 (en) 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
US8986991B2 (en) * 2012-07-03 2015-03-24 Expression Therapeutics, Llc High yield suspension cell line, system and method for making same
EP3404105A1 (de) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Einkettige faktor-viii-polypeptide exprimierende zelllinie und verwendungen davon
WO2014072481A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
SG11201505627RA (en) * 2013-01-24 2015-08-28 Portola Pharm Inc INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES
TWI636062B (zh) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
EP2853538A1 (de) 2013-09-27 2015-04-01 Université Pierre et Marie Curie (Paris 6) Analoge von Temporin-SHa und Verwendungen davon
TN2016000578A1 (en) 2014-07-30 2018-04-04 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
EP3212226B1 (de) 2014-10-31 2020-03-18 NGM Biopharmaceuticals, Inc. Zusammensetzungen und verfahren zur verwendung zur behandlung von stoffwechselerkrankungen
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
WO2016198499A1 (en) 2015-06-09 2016-12-15 Glycotope Gmbh IMPROVED METHOD FOR PRODUCTION OF γ-CARBOXYLATED POLYPEPTIDES
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
CN105219739A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3452102B9 (de) 2016-04-15 2024-09-04 The Trustees of The University of Pennsylvania Gentherapie zur behandlung von hämophilie a
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
EP3625329A1 (de) 2017-05-17 2020-03-25 Octapharma AG Verfahren zur herstellung eines rekombinanten zielproteins
EP3710589A4 (de) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha Anti-c1s-antikörper und verfahren zur verwendung
CN112469821B (zh) * 2018-07-26 2021-12-14 正大天晴药业集团股份有限公司 一种制备重组人凝血因子ⅷ的方法
IL317002A (en) 2018-08-10 2025-01-01 Chugai Pharmaceutical Co Ltd Anti-CD137 antigen binding molecule and use thereof
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
EP3870206A4 (de) 2018-10-23 2023-04-26 The Children's Hospital Of Philadelphia Zusammensetzungen und verfahren zur modulation der faktor-viii-funktion
CN114096562B (zh) 2019-05-15 2025-02-21 中外制药株式会社 抗原结合分子、药物组合物和方法
WO2022259007A1 (en) 2021-06-11 2022-12-15 Sorbonne Universite Short antimicrobial peptides

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74909A (en) * 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
JPS6171774A (ja) * 1984-09-14 1986-04-12 Sony Corp テレビジヨンカメラ装置のビ−ム電流制御装置
JP2584443B2 (ja) * 1985-04-22 1997-02-26 ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド 活性化▲ｉ▼▲ｘ▼因子の高収率産生
JP2525022B2 (ja) * 1986-01-03 1996-08-14 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド ▲ＶＩＩＩ▼：ｃ因子型タンパク質の改良生産方法
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5024939A (en) 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
NZ236094A (en) * 1989-11-17 1993-04-28 Chiron Corp Recombinant protein complex having human factor viii:c activity
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE69101634T4 (de) * 1990-01-26 1994-12-01 Immuno Ag Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
US5445953A (en) * 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
EP0710288B1 (de) * 1993-06-10 2006-04-05 Genetic Therapy, Inc. Adenovirale vektoren für die behandlung der hämophilie
WO1998000541A2 (en) * 1996-07-03 1998-01-08 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of human disease
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
CA2312291A1 (en) * 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
WO2000049147A1 (en) * 1999-02-19 2000-08-24 Octagene Gmbh Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy
WO2001012836A1 (en) * 1999-08-13 2001-02-22 Fred Hutchinson Cancer Research Center Crystal of a truncated protein construct containing a coagulation factor viii c2 domain in the presence or absence of a bound ligand and methods of use thereof
US7572619B2 (en) * 2000-03-22 2009-08-11 Octagene Gmbh Recombinant blood clotting factors
WO2003009237A1 (en) * 2001-07-18 2003-01-30 Skaginn Hf. A method and apparatus for relating information of a processed object to an operator

Also Published As

Publication number Publication date
KR20030011079A (ko) 2003-02-06
EP1266006A2 (de) 2002-12-18
HUP0300588A2 (hu) 2003-06-28
BR0109494A (pt) 2002-12-10
AU2006201848A1 (en) 2006-05-25
EP1460131A3 (de) 2005-06-01
WO2001070968A2 (en) 2001-09-27
ES2254403T3 (es) 2006-06-16
BRPI0109494B1 (pt) 2021-05-11
EA004317B1 (ru) 2004-02-26
EE200200538A (et) 2004-04-15
DK1266006T3 (da) 2006-01-16
MXPA02009221A (es) 2005-07-25
CZ303929B6 (cs) 2013-07-03
JP3894795B2 (ja) 2007-03-22
CN1454257B (zh) 2013-01-16
EP1266006B1 (de) 2005-12-07
IL151857A (en) 2010-05-31
IL151857A0 (en) 2003-04-10
SK287706B6 (en) 2011-07-06
CA2404163C (en) 2009-09-29
KR100581574B1 (ko) 2006-05-22
BE2014C077I2 (de) 2020-01-30
CN1454257A (zh) 2003-11-05
DE60115613D1 (de) 2006-01-12
AU5471501A (en) 2001-10-03
CZ20023166A3 (cs) 2003-02-12
US20040023333A1 (en) 2004-02-05
NO20024475L (no) 2002-11-20
HU228091B1 (en) 2012-10-29
SI1266006T1 (sl) 2006-06-30
FR15C0003I1 (fr) 2015-02-27
JP2003530093A (ja) 2003-10-14
SK15042002A3 (sk) 2003-09-11
DE60115613T2 (de) 2006-08-24
BG65930B1 (bg) 2010-05-31
EP1460131A2 (de) 2004-09-22
WO2001070968A3 (en) 2001-12-13
BRPI0109494B8 (pt) 2021-05-25
NO330910B1 (no) 2011-08-15
BG107152A (bg) 2003-06-30
AU2001254715B2 (en) 2006-02-02
RS50743B (sr) 2010-08-31
CA2404163A1 (en) 2001-09-27
HUP0300588A3 (en) 2005-09-28
HRP20020767A2 (en) 2005-02-28
NO20024475D0 (no) 2002-09-19
FR15C0003I2 (fr) 2015-11-20
US7572619B2 (en) 2009-08-11
YU71002A (sh) 2005-11-28
NZ521732A (en) 2004-05-28
HRP20020767B1 (hr) 2011-09-30
EA200201008A1 (ru) 2003-02-27

Similar Documents

Publication Publication Date Title
DE60115613D1 (de) Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien
DE69841982D1 (de) Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
ATE437221T1 (de) Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
EE05075B1 (et) POL1212 aminohappej„rjestust kodeeriv DNA, seda sisaldav ekspressioonivektor, sea modifitseeritud VIII-tegur, sellel p?hinev ravimkompositsioon ning meetod sea modifitseeritud VIII-teguri aminohappej„rjestust omava valgu valmistamiseks
ATE532858T1 (de) Menschliche gerinnungsfaktor-vii-polypeptide
AU2001254624A1 (en) Human coagulation factor vii variants
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
ATE465266T1 (de) Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren
JPS6485096A (en) Hybrid human protein c and biotechnological synthesis thereof
DE69434689D1 (de) Adenovirale vektoren für die behandlung der hämophilie
AR037038A1 (es) Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto
ATE174629T1 (de) Herstellung von proteinen mittels protein 7b2
ATE513033T1 (de) Expression von proteinen in aus nabelschnurblut gewonnenen endothelzellen
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
DE602004028239D1 (de) Protease, für die protease codierende dna und verfahren zur herstellung der protease
DE69027967D1 (de) Proteine, die die expression von vertebraten-mhc-klasse-ii-genen regulieren, dafür kodierende dna-sequenzen und pharmazeutische zusammensetzungen
EP1679372A4 (de) Neues plexin-polypeptid, dieses codierende dna und verwendung davon
ATE452139T1 (de) Peptid-köder zur herstellung von medikamenten, die für die prävention oder behandlung von autoimmunerkrankungen bzw. problemen, die mit dem auftreten von gegen exogene proteine gerichteten antikörpern in zusammenhang stehen, bestimmt sind

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1266006

Country of ref document: EP

EEFA Change of the company name